News

U.S. Department of Justice Close Investigation PLATO Clinical Trial Ticagrelor

AstraZeneca announced it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial that tested the safety and...

The launch of several drugs with “extraordinary blockbuster potential” will cause the acute coronary syndrome (ACS) treatment market to more than triple in value, from $12.3 billion in 2013 to $43...

Clinical Study Heart Vaccine Pharmaceutical

Researchers at Wayne State University have made a fundamental discovery and, in subsequent collaboration with scientists at La Jolla Institute for Allergy and Immunology (LIAI), are one step...

July 30, 2014 — Regado Biosciences announced earlier this month it has voluntarily paused enrollment in its REGULATE-PCI trial, which was testing the safety and effectiveness of its Revolixys...

statins, pharmaceuticals, cholesterol

A new study by researchers at Wake Forest Baptist Medical Center suggests that the use of cholesterol-lowering statins may help prolong the lives of people with diabetic cardiovascular...

CVS Caremark Study Copay Heart Attack Non-white Patient Outcomes

A study by researchers at CVS Caremark, Aetna and Brigham and Women’s Hospital published in the May issue of Health Affairs, finds that eliminating copays for preventive medications...

LipoScience Inc. announced the publication of the first large-scale real world study evidencing a link between low LDL-P and reduced cardiovascular disease (CVD) risk.

The U.S. Food and Drug Administration (FDA) has completed its safety review and has found no clear evidence of increased cardiovascular risks associated with use of the blood pressure medication...

Less aggressive anticoagulation therapy, combined with low-dose aspirin, can be used safely in conjunction with a newer generation mechanical heart valve. These findings from the first phase of a...

June 17, 2014 — AtheroNova Inc. received a Notice of Issuance for an additional compound for cardiovascular treatments. This patent issuance further exemplifies a plan to develop a broad platform...

Mast Therapeutics Failure MST-188 Clinical Study Pharmaceuticals

Mast Therapeutics Inc. announced that, in a placebo-controlled, nonclinical model of chronic heart failure, MST-188 demonstrated a statistically significant improvement in numerous parameters of...

June 5, 2014 — Mercator MedSystems is in the midst of its prospective, 300-patient, 30-site DANCE (Dexamethasone to the Adventitia to eNhance Clinical Efficacy) clinical trial to study a new...

Strokes kill nearly 130,000 Americans every year, according to the Centers for Disease Control and Prevention. Because approximately 30 percent of strokes are caused by blockages in the carotid...

June 3, 2014 — The U.S. Food and Drug Administration (FDA) announced it approved Zontivity (vorapaxar) tablets to reduce the risk of heart attack, stroke, cardiovascular death and need for...

Alere announced a class I recall of its INRatio2 PT/INR professional test strips, part of the Alere lNRatio2 PT/INR monitoring system (professional use) which also consists of the INRatio2 monitor...

Hospira Inc. issued a nationwide recall to the user level for one lot of Dobutamine Injection, USP, 250 mg, 20 mL, single-dose fliptop vial, (NDC 0409-2344-02), Lot 27-352-DK. (NDC and lot number...

The National Lipid Assn. (NLA) released a draft summary that highlights key aspects of care that provide a thorough supplement and direction for clinicians treating patients with dyslipidemia.

New data presented for the first time at the World Heart Federation’s World Congress of Cardiology 2014 shows a significant improvement in both patient adherence and risk factor control when...

May 6, 2014 — The National Lipid Association (NLA) recently convened an expert panel to examine various aspects of statin safety and statin tolerance. Results of the symposium findings...

April 29, 2014 — Armetheon Inc. announced it has reached agreement with the U.S. Food and Drug Administration (FDA) on a special protocol assessment (SPA) for the final pivotal trial of tecarfarin...